Hanish Arnold C's Form 4 filing
Decoy Therapeutics Inc. (DCOY) · filed Nov 24, 2025
- Accession no.
- 0001615219-25-000193
- Filed
- Nov 24, 2025
- Trade date
- Nov 20, 2025
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market purchases total $3.75K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Hanish Arnold CCIK 0001233253 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 20, 2025 | Common Stock | PPurchaseAcquired | +5,000 | $0.75F1 | +$3,750 | 5,015 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.7437 to $0.75, inclusive. The reporting person undertakes to provide to Salarius Pharmaceuticals, Inc., any security holder of Salarius Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4.
Referenced by the price of 1 transaction in Table I.